Apimeds Pharmaceuticals (NYSE American: APUS) plans 1-for-10 reverse stock split on July 24
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Apimeds Pharmaceuticals US, Inc. will implement a 1-for-10 reverse stock split of its issued and outstanding common stock. The company plans to file a charter amendment with the Delaware Secretary of State on or about July 23, 2026, and has set the reverse split to become effective as of 12:01 a.m. Eastern Time on July 24, 2026.
Following effectiveness, every ten shares of common stock will automatically be combined into one share, and the stock is expected to begin trading on a split-adjusted basis on the NYSE American under the symbol APUS at the open of trading on July 24, 2026. The new CUSIP for the common stock will be 03771D201. Stockholders previously approved the reverse split by majority written consent on December 1, 2025, after which an information statement was mailed and the required waiting period has elapsed.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Reverse stock split ratio: 1-for-10
Effective time of reverse split: 12:01 a.m. Eastern Time on July 24, 2026
Planned filing date of charter amendment: On or about July 23, 2026
+3 more
6 metrics
Reverse stock split ratio
1-for-10
Every ten shares of issued and outstanding common stock will be combined into one share
Effective time of reverse split
12:01 a.m. Eastern Time on July 24, 2026
Time at which the reverse stock split will become effective
Planned filing date of charter amendment
On or about July 23, 2026
Expected date to file Charter Amendment with Delaware Secretary of State
New CUSIP for common stock
03771D201
CUSIP number for Apimeds Pharmaceuticals’ common stock following the reverse stock split
Stockholder approval date
December 1, 2025
Date stockholders holding a majority of voting power approved the reverse stock split by written consent
Information Statement mailing date
March 5, 2026
Date the Information Statement regarding the reverse stock split was first mailed to stockholders
Key Terms
Reverse Stock Split, Written Consent, Information Statement, Emerging growth company, +1 more
5 terms
Reverse Stock Split financial
"to effect a reverse stock split of its issued and outstanding shares of common stock"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
Written Consent regulatory
"by written consent (the “Written Consent”), to effect a reverse stock split"
A written consent is a formal, signed document in which shareholders or directors approve a corporate action without holding a live meeting, similar to signing a petition instead of gathering in person. It matters to investors because it can speed decisions, create a clear legal record of approval, and affect control or governance outcomes — for example enabling changes that would otherwise require a vote at a meeting.
Information Statement regulatory
"filed and mailed an information statement (the “Information Statement”) to its stockholders"
An information statement is a formal document companies distribute to investors and the public to explain important facts about a corporate action, transaction, or situation — for example changes in management, business plans, or financial events. It’s like a clear, written notice that lays out what happened and why it matters, helping investors judge risk and make decisions without being asked to vote. Reliable, timely information can affect share prices and investor trust.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Charter Amendment regulatory
"to amend the Company’s Amended and Restated Certificate of Incorporation (the “Charter Amendment”)"
A charter amendment is a formal change to a corporation’s founding document — its legal rulebook that sets basic structure, powers and shareholder rights. Investors care because amending the charter can alter voting rules, share classes, dividend policies or takeover protections, which can change how value and control are distributed; think of it as revising a building’s blueprint that affects who owns which rooms and who can remodel next.
FAQ
What reverse stock split did Apimeds Pharmaceuticals (APUS) approve?
Apimeds Pharmaceuticals approved a 1-for-10 reverse stock split of its common stock. Every ten existing shares will be automatically combined and changed into one share of issued and outstanding common stock upon effectiveness.
When does the Apimeds Pharmaceuticals (APUS) reverse stock split become effective?
The reverse stock split becomes effective at 12:01 a.m. Eastern Time on July 24, 2026. The company expects to file the related charter amendment on or about July 23, 2026, with split-adjusted trading beginning July 24, 2026.
When will Apimeds Pharmaceuticals (APUS) start trading on a split-adjusted basis?
Apimeds Pharmaceuticals expects its common stock to begin trading on a split-adjusted basis on the NYSE American at the open of trading on July 24, 2026, following effectiveness of the 1-for-10 reverse stock split.
What is the new CUSIP for Apimeds Pharmaceuticals (APUS) after the reverse split?
After the reverse stock split, the common stock of Apimeds Pharmaceuticals will have a new CUSIP of 03771D201. The shares will continue to trade on the NYSE American under the symbol APUS on a split-adjusted basis.
Why did Apimeds Pharmaceuticals (APUS) change the original effective date of the reverse split?
The company had previously anticipated a March 26, 2026 effective date but did not file the charter amendment then. It now expects effectiveness at 12:01 a.m. Eastern Time on July 24, 2026 after the waiting period has passed.